Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR5 | P61964 | 5/20 | 0.94 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.94 |
| ▸ | RBBP5 | Q15291 | 5/20 | 0.94 |
| ▸ | DPY30 | Q9C005 | 5/20 | 0.94 |
| ▸ | ASH2L | Q9UBL3 | 5/20 | 0.94 |
| ▸ | EZH2 | Q15910 | 3/20 | 0.81 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.77 |
| ▸ | NNMT | P40261 | 8/20 | 0.74 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23120170 | 1.00 | WDR5 (0.94) | WDR5KMT2ARBBP5DPY30ASH2L | |
| SCHEMBL23120420 | 0.97 | WDR5 (1.00) | WDR5KMT2ARBBP5DPY30ASH2L | |
| SCHEMBL23120423 | 0.97 | WDR5 (1.00) | WDR5KMT2ARBBP5DPY30ASH2L | |
| SCHEMBL23120191 | 0.94 | WDR5 (0.84) | WDR5KMT2ARBBP5DPY30ASH2L | |
| SCHEMBL23120187 | 0.94 | WDR5 (0.84) | WDR5KMT2ARBBP5DPY30ASH2L | |
| SCHEMBL29743108 | 0.94 | WDR5 (0.83) | WDR5KMT2ARBBP5DPY30ASH2L | |
| SCHEMBL23120582 | 0.94 | WDR5 (0.88) | WDR5KMT2ARBBP5DPY30ASH2L | |
| SCHEMBL23120585 | 0.94 | WDR5 (0.88) | WDR5KMT2ARBBP5DPY30ASH2L | |
| SCHEMBL23120232 | 0.92 | WDR5 (0.81) | WDR5KMT2ARBBP5DPY30ASH2L | |
| SCHEMBL23120237 | 0.92 | WDR5 (0.81) | WDR5KMT2ARBBP5DPY30ASH2L |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021053158-A1 | NOVEL HISTONE METHYLTRANSFERASE INHIBITORS | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2021-03-25 | — | — | WO | claimed |
| US-20220184195-A1 | INHIBITION OF HISTONE METHYL TRANSFERASES TO TREAT CANCER | ALBERT-LUDWIGS-UNIVERSITAT FREIBURG (DE) | 2022-06-16 | — | — | US | disclosed |
| WO-2021053158-A1 | NOVEL HISTONE METHYLTRANSFERASE INHIBITORS | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2021-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220184195-A1 | INHIBITION OF HISTONE METHYL TRANSFERASES TO TREAT CANCER | KMT2A, KMT5A, DOT1L | WDR5 357/4885KMT2A 1/4885RBBP5 316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.